Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net revenue:
Total net revenues	$ 2,736	$ 2,529
Cost of goods sold	1,149	1,038
Gross margin	1,587	1,491
Operating expenses:
Research and development	556	563
Depreciation and amortization	50	46
Selling, general and administrative	1,999	1,950
Change in fair value of contingent consideration		(42)
Total operating expenses	2,605	2,517
Loss from operations	(1,018)	(1,026)
Other (expense) income:
Interest expense	(13)	(43)
Interest income	3	1
Extinguishment of PPP loan	482
Other (expense) income, net	9	(30)
Total other (expense) income:	481	(72)
Net loss	(537)	(1,098)
Less: Undeclared deemed dividend attributable to noncontrolling interest	(59)	(59)
Net loss attributable to Nephros, Inc. shareholders	$ (596)	$ (1,157)
Net loss per common share, basic and diluted	$ (.06)	$ (.13)
Weighted average common shares outstanding, basic and diluted	9,883,035	8,590,230
Comprehensive loss:
Net loss	$ (537)	$ (1,098)
Other comprehensive loss, foreign currency translation adjustments, net of tax	(6)	(1)
Comprehensive loss	(543)	(1,099)
Comprehensive loss attributable to noncontrolling interest	(59)	(59)
Comprehensive loss attributable to Nephros, Inc. shareholders	(602)	(1,158)
Product Revenues [Member]
Net revenue:
Total net revenues	2,712	2,475
Royalty and Other Revenues [Member]
Net revenue:
Total net revenues	$ 24	$ 54